Neuropathic pain in patients with Charcot-Marie-Tooth type 1A

  • Bogdan Bjelica
  • Stojan PericEmail author
  • Ivana Basta
  • Ivo Bozovic
  • Aleksandra Kacar
  • Ana Marjanovic
  • Vukan Ivanovic
  • Marija Brankovic
  • Milena Jankovic
  • Ivana Novakovic
  • Vidosava Rakocevic Stojanovic
Original Article



Only several studies analyzed the characteristics of neuropathic pain (NeP) more extensively in patients with Charcot-Marie-Tooth type 1A (CMT1A). Therefore, we sought to determine the frequency and features of NeP in CMT1A patients and to assess the association between NeP and sociodemographic and clinical characteristics of patients with CMT1A.


Our research included 51 genetically diagnosed CMT1A patients. The International Association for the Study of Pain (IASP) criteria were used for diagnosis of NeP. PainDETECT questionnaire (PD-Q) was used to assess NeP features. The Medical Research Council (MRC) Sum Score, CMT Neuropathy Score (CMTNS), Overall Neuropathy Limitation Scale (ONLS) score, and Beck Depression Inventory were also used.


NeP was present in 15 (29.4%) patients with CMT1A. The average intensity of pain was 5.7 ± 2.2 out of 10. The most sensitive neuropathic symptoms were numbness, then tingling, and burning sensations, while the most specific symptom was allodynia. Patients with NeP more frequently reported pain in the back (p < 0.01) and the trunk (p < 0.05). Patients with NeP had more pronounced disability of the upper extremities and overall disability, as assessed by the ONLS score (p < 0.05). Depression was more frequent in patients with NeP compared with patients without NeP (66.7 to 13.9%, p < 0.01).


NeP was present in almost one-third of the patients with CMT1A and it was moderate on average. Presence of NeP was associated with worse functional disability and depression.


Charcot-Marie-Tooth disease type 1A Neuropathic pain Disability Depression 


Compliance with ethical standards

This study was approved by the Ethical Committee of the Faculty of Medicine, University of Belgrade, and informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Braathen GJ, Sand JC, Lobato A, Høyer H, Russell MB (2011) Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 18:39–48CrossRefGoogle Scholar
  2. 2.
    Saporta MA (2014) Charcot-Marie-Tooth disease and other inherited neuropathies. Continuum (MinneapMinn) 20:1208–1225Google Scholar
  3. 3.
    Jani-Ascadi, Krajewski K, Shy ME (2008) Charcot-Marie-Tooth: diagnosis and management. Semin Neurol 29:185–194CrossRefGoogle Scholar
  4. 4.
    Murphy SM, Laura M, Fawcett K et al (2012) Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 83:706–710CrossRefGoogle Scholar
  5. 5.
    Lupski JR, De Oca-Luna RM, Slaugenhaupt S et al (1991) DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66:219–232CrossRefGoogle Scholar
  6. 6.
    Haanpää ML, Backonja MM, Bennett MI et al (2009) Assessment of neuropathic pain in primary care. Am J Med 122:13–21CrossRefGoogle Scholar
  7. 7.
    Pazzaglia C, Vollono C, Ferraro D, Virdis D, Lupi V, le Pera D, Tonali P, Padua L, Valeriani M (2010) Mechanisms of neuropathic pain in patients with Charcot-Marie Tooth 1A: a laser-evoked potential study. Pain 149:379–385CrossRefGoogle Scholar
  8. 8.
    Ribiere C, Bernardin M, Sacconi S, Delmont E, Fournier-Mehouas M, Rauscent H, Benchortane M, Staccini P, Lantéri-Minet M, Desnuelle C (2012) Pain assessment in Charcot-Marie-Tooth (CMT) disease. Ann Phys Rehabil Med 55(3):160–173CrossRefGoogle Scholar
  9. 9.
    Laurà M, Hutton EJ, Blake J, Lunn MP, Fox Z, Pareyson D, Solari A, Radice D, Koltzenburg M, Reilly MM (2014) Pain and small fiber function in Charcot-Marie-Tooth disease type 1A. Muscle Nerve 50(3):366–371CrossRefGoogle Scholar
  10. 10.
    Aarskog NK, Vedeler CA (2000) Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107(5):494–498CrossRefGoogle Scholar
  11. 11.
    Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14(11):1103–1109CrossRefGoogle Scholar
  12. 12.
    Shy ME, Blake J, Krajewski K et al (2005) Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64(7):1209–1214CrossRefGoogle Scholar
  13. 13.
    Graham R, Hughes R (2006) A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 77(8):973–976CrossRefGoogle Scholar
  14. 14.
    Beck AT, Steer RA, Carbin MG (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8(1):77–100CrossRefGoogle Scholar
  15. 15.
    Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18):1630–1635CrossRefGoogle Scholar
  16. 16.
    Freynhagen R, Baron R, Gockel U, Tölle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920CrossRefGoogle Scholar
  17. 17.
    Carter GT, Jensen MP, Galer BS, Kraft GH, Crabtree LD, Beardsley RM, Abresch RT, Bird TD (1998) Neuropathic pain in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil 79:1560–1564CrossRefGoogle Scholar
  18. 18.
    Ramchandren S, Jaiswal M, Feldman E, Shy M (2014) Effect of pain in pediatric inherited neuropathies. Neurology 82(9):793–797CrossRefGoogle Scholar
  19. 19.
    Jensen MP, Abresch RT, Carter GT, McDonald CM (2005) Chronic pain in persons with neuromuscular disease. Arch Phys Med Rehabil 86(6):1155–1163CrossRefGoogle Scholar
  20. 20.
    Abresch RT, Carter GT, Jensen MP, Kilmer DD (2002) Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Med 19:39–48CrossRefGoogle Scholar
  21. 21.
    Tiffreau V, Viet G, Thevenon A (2006) Pain and neuromuscular disease. Am J Phys Med Rehabil 85(9):756–766CrossRefGoogle Scholar
  22. 22.
    Singleton JR (2005) Evaluation and treatment of painful peripheral polyneuropathy. Semin Neurol 25:185–195CrossRefGoogle Scholar
  23. 23.
    Van Paassen B, Van der Kooi A, Spaendonck-Zwarts VK, Verhamme C, Baas F, De Visser M (2014) PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies. Orphanet J Rare Dis 9:38CrossRefGoogle Scholar
  24. 24.
    Liao JP, Waclawik AJ (2004) Nerve root hypertrophy in CMT type 1A. Neurology 62(5):783CrossRefGoogle Scholar
  25. 25.
    Argoff CE (2007) The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 23(1):15–22CrossRefGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  • Bogdan Bjelica
    • 1
  • Stojan Peric
    • 1
    Email author
  • Ivana Basta
    • 1
  • Ivo Bozovic
    • 1
  • Aleksandra Kacar
    • 1
  • Ana Marjanovic
    • 1
  • Vukan Ivanovic
    • 1
  • Marija Brankovic
    • 1
  • Milena Jankovic
    • 1
  • Ivana Novakovic
    • 2
  • Vidosava Rakocevic Stojanovic
    • 1
  1. 1.Neurology Clinic, Clinical Center of Serbia, Faculty of MedicineUniversity of BelgradeBelgradeSerbia
  2. 2.Institute of Human Genetics, School of MedicineUniversity of BelgradeBelgradeSerbia

Personalised recommendations